Endolytix is a biotech company that develops therapeutic approaches that address intrinsic antibiotic resistance in NTM infections.
Endolytix has raised $5.0M in total funding. The most recent round was Debt Financing. The last funding was announced in August 2024.
Endolytix's investors include Morningside.
Endolytix is headquartered in Beverly, United States.
Endolytix is a biotech company that develops therapeutic approaches that address intrinsic antibiotic resistance in NTM infections.
Endolytix is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endolytix — Funding & Investors." VCBacked, August 7, 2024, https://www.vcbacked.co/company/endolytix. Accessed August 14, 2026.
VCBacked. (2024). Endolytix — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/endolytix
{{cite web |title=Endolytix — Funding & Investors |url=https://www.vcbacked.co/company/endolytix |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated